Cargando…
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in glioblastoma. This Phase I study was initiated to evaluate the tolerability and safety of asunercept in combination with st...
Autores principales: | Wei, Kuo-Chen, Hsu, Peng-Wei, Tsai, Hong-Chieh, Lin, Ya-Jui, Chen, Ko-Ting, Toh, Cheng-Hong, Huang, Hui-Lin, Jung, Shih-Ming, Tseng, Chen-Kan, Ke, Yu-Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674255/ https://www.ncbi.nlm.nih.gov/pubmed/34911992 http://dx.doi.org/10.1038/s41598-021-02527-1 |
Ejemplares similares
-
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022) -
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
por: Krendyukov, Andriy, et al.
Publicado: (2019) -
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022) -
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
por: Wick, Wolfgang, et al.
Publicado: (2019) -
Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review
por: Su, Jiahao, et al.
Publicado: (2016)